Abstract
Dengue virus is a major and rapidly growing public health concern in tropic and subtropic regions across the globe. In late 2018, Senegal experienced its largest dengue virus outbreak to date, covering several regions. However, little is known about the genetic diversity of dengue virus (DENV) in Senegal. Here we used molecular tools including metagenomic sequencing to identify 19 previously undetected dengue virus cases from the city of Thiès and assemble 17 complete virus genomes. DENV3 was the most frequent serotype; 11 sequences (65%) were DENV3, 4 sequences were DENV2 and 2 were DENV1. Sequences were closest to recent sequences from West Africa, suggesting ongoing local circulation of viral populations; however, detailed inference is limited by the scarcity of available genomic data. We did not find clear associations with reported clinical signs or symptoms, highlighting the importance of testing for diagnosing febrile diseases. Overall, these findings expand the known range of DENV in Senegal, and underscore the need for better genomic characterization of DENV in West Africa.
Competing Interest Statement
P.C.S. is a co-founder and shareholder of Sherlock Biosciences, and a Board member and shareholder of Danaher Corporation. The other authors declare no competing interests.
Funding Statement
This work is supported by grants from the National Institute of Allergy and Infectious Diseases; NIH-H3Africa (U54HG007480) and the West African Emerging Infectious Diseases Research Center (U01AI151812). K.J.S. is supported by the ASTMH Centennial Award. P.C.S. is an investigator supported by the Howard Hughes Medical Institute (HHMI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient samples were obtained through a study approved by the Institutional Review Boards at the Senegalese Ministry of Health and Harvard University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
